^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HS-10502

    i
    Other names: HS-10502, HS10502, HS 10502
    Associations

    News

    Trials
    Company:
    Jiangsu Hansoh Pharma
    Drug class:
    PARP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    HS-10502 Combination Treatment in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=157, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • docetaxel • AiTan (rivoceranib) • albumin-bound paclitaxel • irinotecan • GSK5733584 • GSK5764227 • HS-10502
    11ms
    HS-10502 Combination Treatment in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=154, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial
    |
    Avastin (bevacizumab) • docetaxel • AiTan (rivoceranib) • albumin-bound paclitaxel • irinotecan • GSK5733584 • GSK5764227 • HS-10502
    2years
    A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=318, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HRD
    |
    HS-10502
    almost3years
    A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=318, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial • Metastases
    |
    HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HRD
    |
    HS-10502